Market Cap 5.30B
Revenue (ttm) 434.43M
Net Income (ttm) 275.19M
EPS (ttm) N/A
PE Ratio 138.00
Forward PE N/A
Profit Margin 63.35%
Debt to Equity Ratio 0.00
Volume 663,576
Avg Vol 1,280,414
Day's Range N/A - N/A
Shares Out 62.52M
Stochastic %K 68%
Beta 2.22
Analysts Strong Sell
Price Target $89.77

Company Profile

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 474 0170
Address:
7707 Gateway Boulevard, Suite 140, Newark, United States
LezGoh
LezGoh Nov. 14 at 1:42 PM
$BEAM $PTGX $SRPT $VKTX it’ll be $SRPT imo. That’s close to getting acquired look at funds loading up.
0 · Reply
blueb22
blueb22 Nov. 14 at 1:39 PM
$VKTX $PTGX $SRPT $BEAM - Merck buying Cidara for $9.2 B - at $220, which is 115 premium to Yesterday's price, and stock was just $25 till July. Wow!!! Whoever was holding prior to July will make 9x. Even with this BO news Biotechs are down due to bad overall market and as always panic selling and short attack. This Merck BO should suggest VKTX should atleast get $120-140 in BO deal for these Obesity advance pipeline and MASH . I think it is coming. Other Biotechs like SRPT and BEAM should also get fat premium offers. J&J was in talk to buy PTGX last month but then there is no update, I think they will be bought in $120-130 range soon (should be even more)
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:34 AM
$PTGX is currently trading at $83.24, showing a strong upward momentum as indicated by an RSI of 68.64, which suggests it is nearing overbought conditions. The price is well above both the 30-day moving average (MA30) of 76.28 and the 50-day moving average (MA50) of 70.57, reinforcing a bullish trend. However, caution is advised as the RSI indicates potential overextension. Market context shows the 60-day high at $93.25, providing a potential resistance level, while the 60-day low at $54.5 offers a solid support base. Suggested entry point is at $82.50, slightly below the last close to allow for a better risk-reward ratio. Set a stop loss at $80.00 to manage downside risk. Target 1 is set at $90.00, approaching the 60-day high, while Target 2 is at $93.00, just below the resistance level. Monitor closely for any signs of reversal given the RSI level. https://privateprofiteers.com
0 · Reply
Mrstock2255
Mrstock2255 Nov. 14 at 12:58 AM
0 · Reply
Quantumup
Quantumup Nov. 13 at 12:51 PM
Jefferies🏁 $ORKA Buy/$45 $ABBV $JNJ $PTGX $NVS LLY UCBJY Jefferies in its initiation said: We like two YTE modified, long-acting mAbs with de-risked IL23/ IL17 targets for favorable less frequent dosing, and pot'ly greater efficacy. FIH PK of ORKA-001 (IL23) at EADV25 showed ~100-day half life, reaching bull case and supporting annual dosing. ORKA-002 (IL17) FIH PK is ~YE25 targeting ~50-/75-day half life. We see meaningful upside pot'l from Ph2a '001 POC study in PsO with readout in 2H26, followed by '002 ~6mo later. We initiate at Buy, with PT $45.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:40 AM
$PTGX is currently trading at $85.56, exhibiting a strong bullish trend indicated by an RSI of 78.02, suggesting overbought conditions. The price is above both the 30-day MA of 74.97 and the 50-day MA of 69.56, reinforcing the bullish momentum. However, the elevated RSI indicates potential for a pullback. Given the 60-day high of $93.25, there is room for upward movement, but caution is warranted due to the risk of a correction. A suggested entry point could be around $84.00, anticipating a small retracement. A stop-loss can be placed at $81.50 to manage risk. Targets are set at $90.00 and $93.00, aligning with the recent high and providing a favorable risk-reward ratio. Monitor the RSI for signs of divergence as the trade progresses. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
blueb22
blueb22 Nov. 12 at 3:32 AM
$PTGX - J&J will have to now rush to finish negotiations and announce BO. They can not wait longer, otherwise will have to pay higher valuation as SP is in consistent uptrend in last few days. rotation into Biotech is and will help here as well. Hope for the best. youtube.com/watch%3Fv%3Dh1Q......
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:16 AM
$PTGX is currently trading at $85.56, exhibiting a strong bullish trend indicated by an RSI of 78.02, suggesting overbought conditions. The price is above both the 30-day MA of 74.97 and the 50-day MA of 69.56, reinforcing the bullish momentum. However, the elevated RSI indicates potential for a pullback. Given the 60-day high of $93.25, there is room for upward movement, but caution is warranted due to the risk of a correction. A suggested entry point could be around $84.00, anticipating a small retracement. A stop-loss can be placed at $81.50 to manage risk. Targets are set at $90.00 and $93.00, aligning with the recent high and providing a favorable risk-reward ratio. Monitor the RSI for signs of divergence as the trade progresses. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 9:56 PM
Citigroup has updated their rating for Protagonist Therapeutics ( $PTGX ) to Buy with a price target of 98.
0 · Reply
blueb22
blueb22 Nov. 10 at 5:27 PM
$VKTX $SRPT $PTGX $BEAM $NTLA - In JPM Healthcare conferences 13-14 Jan 2026, featured sessions include "Pharma's Big Bet and the Resurgence of M&A", "Next-gen Partnerships: Unlocking Speed, Scale, and Value in Clinical Development", and most important for VKTX (and metabolic players) is "GLP-1s and the Next Waves in Obesity Therapies" Will be very interesting. And bullish for VKTX
0 · Reply
Latest News on PTGX
Johnson & Johnson in Talks to Buy Protagonist Therapeutics

Oct 10, 2025, 11:13 AM EDT - 5 weeks ago

Johnson & Johnson in Talks to Buy Protagonist Therapeutics

JNJ


Protagonist Therapeutics Reports Granting of Inducement Award

Apr 16, 2025, 4:05 PM EDT - 7 months ago

Protagonist Therapeutics Reports Granting of Inducement Award


Overlooked Stock: PTGX

Mar 10, 2025, 4:57 PM EDT - 8 months ago

Overlooked Stock: PTGX


Why Is Protagonist Therapeutics Stock Trading Higher On Monday?

Mar 10, 2025, 10:04 AM EDT - 8 months ago

Why Is Protagonist Therapeutics Stock Trading Higher On Monday?


Protagonist Therapeutics Reports Granting of Inducement Awards

Jan 6, 2025, 4:05 PM EST - 11 months ago

Protagonist Therapeutics Reports Granting of Inducement Awards


LezGoh
LezGoh Nov. 14 at 1:42 PM
$BEAM $PTGX $SRPT $VKTX it’ll be $SRPT imo. That’s close to getting acquired look at funds loading up.
0 · Reply
blueb22
blueb22 Nov. 14 at 1:39 PM
$VKTX $PTGX $SRPT $BEAM - Merck buying Cidara for $9.2 B - at $220, which is 115 premium to Yesterday's price, and stock was just $25 till July. Wow!!! Whoever was holding prior to July will make 9x. Even with this BO news Biotechs are down due to bad overall market and as always panic selling and short attack. This Merck BO should suggest VKTX should atleast get $120-140 in BO deal for these Obesity advance pipeline and MASH . I think it is coming. Other Biotechs like SRPT and BEAM should also get fat premium offers. J&J was in talk to buy PTGX last month but then there is no update, I think they will be bought in $120-130 range soon (should be even more)
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:34 AM
$PTGX is currently trading at $83.24, showing a strong upward momentum as indicated by an RSI of 68.64, which suggests it is nearing overbought conditions. The price is well above both the 30-day moving average (MA30) of 76.28 and the 50-day moving average (MA50) of 70.57, reinforcing a bullish trend. However, caution is advised as the RSI indicates potential overextension. Market context shows the 60-day high at $93.25, providing a potential resistance level, while the 60-day low at $54.5 offers a solid support base. Suggested entry point is at $82.50, slightly below the last close to allow for a better risk-reward ratio. Set a stop loss at $80.00 to manage downside risk. Target 1 is set at $90.00, approaching the 60-day high, while Target 2 is at $93.00, just below the resistance level. Monitor closely for any signs of reversal given the RSI level. https://privateprofiteers.com
0 · Reply
Mrstock2255
Mrstock2255 Nov. 14 at 12:58 AM
0 · Reply
Quantumup
Quantumup Nov. 13 at 12:51 PM
Jefferies🏁 $ORKA Buy/$45 $ABBV $JNJ $PTGX $NVS LLY UCBJY Jefferies in its initiation said: We like two YTE modified, long-acting mAbs with de-risked IL23/ IL17 targets for favorable less frequent dosing, and pot'ly greater efficacy. FIH PK of ORKA-001 (IL23) at EADV25 showed ~100-day half life, reaching bull case and supporting annual dosing. ORKA-002 (IL17) FIH PK is ~YE25 targeting ~50-/75-day half life. We see meaningful upside pot'l from Ph2a '001 POC study in PsO with readout in 2H26, followed by '002 ~6mo later. We initiate at Buy, with PT $45.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:40 AM
$PTGX is currently trading at $85.56, exhibiting a strong bullish trend indicated by an RSI of 78.02, suggesting overbought conditions. The price is above both the 30-day MA of 74.97 and the 50-day MA of 69.56, reinforcing the bullish momentum. However, the elevated RSI indicates potential for a pullback. Given the 60-day high of $93.25, there is room for upward movement, but caution is warranted due to the risk of a correction. A suggested entry point could be around $84.00, anticipating a small retracement. A stop-loss can be placed at $81.50 to manage risk. Targets are set at $90.00 and $93.00, aligning with the recent high and providing a favorable risk-reward ratio. Monitor the RSI for signs of divergence as the trade progresses. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
blueb22
blueb22 Nov. 12 at 3:32 AM
$PTGX - J&J will have to now rush to finish negotiations and announce BO. They can not wait longer, otherwise will have to pay higher valuation as SP is in consistent uptrend in last few days. rotation into Biotech is and will help here as well. Hope for the best. youtube.com/watch%3Fv%3Dh1Q......
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:16 AM
$PTGX is currently trading at $85.56, exhibiting a strong bullish trend indicated by an RSI of 78.02, suggesting overbought conditions. The price is above both the 30-day MA of 74.97 and the 50-day MA of 69.56, reinforcing the bullish momentum. However, the elevated RSI indicates potential for a pullback. Given the 60-day high of $93.25, there is room for upward movement, but caution is warranted due to the risk of a correction. A suggested entry point could be around $84.00, anticipating a small retracement. A stop-loss can be placed at $81.50 to manage risk. Targets are set at $90.00 and $93.00, aligning with the recent high and providing a favorable risk-reward ratio. Monitor the RSI for signs of divergence as the trade progresses. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 9:56 PM
Citigroup has updated their rating for Protagonist Therapeutics ( $PTGX ) to Buy with a price target of 98.
0 · Reply
blueb22
blueb22 Nov. 10 at 5:27 PM
$VKTX $SRPT $PTGX $BEAM $NTLA - In JPM Healthcare conferences 13-14 Jan 2026, featured sessions include "Pharma's Big Bet and the Resurgence of M&A", "Next-gen Partnerships: Unlocking Speed, Scale, and Value in Clinical Development", and most important for VKTX (and metabolic players) is "GLP-1s and the Next Waves in Obesity Therapies" Will be very interesting. And bullish for VKTX
0 · Reply
outlawinvestor1
outlawinvestor1 Nov. 10 at 1:30 PM
$IFRX $PTGX congrats to all investors. i reiterate that i think a fixed-dosed combination w/ an il17a/f would be a game changer.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 8:09 PM
JP Morgan has updated their rating for Protagonist Therapeutics ( $PTGX ) to Overweight with a price target of 81.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 3:48 PM
Barclays updates rating for Protagonist Therapeutics ( $PTGX ) to Overweight, target set at 72 → 88.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 2:13 PM
Citizens updates rating for Protagonist Therapeutics ( $PTGX ) to Market Outperform, target set at 69 → 102.
0 · Reply
Quantumup
Quantumup Nov. 7 at 11:47 AM
Clear Street⬆️ $PTGX to $91/reitd Buy $TAK $JNJ $ABBV $ABVX Clear Street said: Model Update - we're increasing our PT to $91 from $74. Our revised model increases peak penetration for rusfertide in polycythemia vera (PV) to 25% (from 20%), driven by the drug's convenient self-administration (and auto-injector) potential, which could significantly enhance patient adherence and uptake. We're also increasing our POS for the Crohn's disease market model to 75% from 50%, despite not yet seeing any data for this indication. This adjustment is based on precedent: although Crohn's remains a more challenging target, drugs that succeed in UC frequently demonstrate efficacy in Crohn's, whereas failure in UC seldom justifies continued Crohn's development. Notably, industry leaders in IL-23 inhibition-STELARA (ustekinumab) and SKYRIZI-achieved their best clinical outcomes in Crohn's after initially establishing evidence in UC, with early Crohn's decisions made before patient-level data were available.
0 · Reply
d_risk
d_risk Nov. 7 at 12:50 AM
$PTGX - Protagonist Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors PTGX flags new risks from potential FDA/government disruptions, macroeconomic instability (inflation, tariffs, trade policy), and ongoing stock price volatility, all of which could seriously impact its business and valuation. #Biotechnology #PharmaceuticalIndustry #StockVolatility #MacroeconomicInstability #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/PTGX/10-Q/2025-11-06
0 · Reply
justiceforb_85
justiceforb_85 Nov. 6 at 1:47 AM
$PTGX outstanding data for icotrokinra in plaque psoriasis. This should be worth much more, especially if oral IL-17 agent is successful. https://www.nejm.org/doi/full/10.1056/NEJMoa2504187?query=featured_home
0 · Reply
Quantumup
Quantumup Nov. 4 at 11:23 AM
Citizens reiterated $ABVX Market Outperform/$114 $PTGX - $JNJ $ABBV $LLY PFE Citizens JMP said in its note: Additional data from the Phase 3 ABTECT induction studies underscore improvement in quality of life with obefazimod treatment; we reiterate our Market Outperform rating and $114 risk-adjusted, DCF-derived price target on Abivax. Yesterday afternoon, Abivax announced patient-reported data from the Phase 3 ABTECT induction studies underscoring an improvement in patient quality of life with obefazimod treatment. In our view, these results support high patient compliance and reinforce our view in the differentiated clinical profile of obefazimod.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Nov. 2 at 12:54 AM
showing why i wait for H% to reset on $PTGX before entering
0 · Reply
outlawinvestor1
outlawinvestor1 Nov. 1 at 10:23 PM
$IFRX i wish inflarx and $PTGX would join forces for hs. i think an oral c5aR1 inhibitor + il-17a/f would be a super combo for treating hs among other il-17 driven autoimmune diseases.
1 · Reply
outlawinvestor1
outlawinvestor1 Oct. 30 at 10:47 PM
$PTGX new pys estimates for ico from leerink.
0 · Reply
blueb22
blueb22 Oct. 29 at 2:36 AM
$PTGX - it is up total 6% (4.3% during regular hours + 1.8% AH), and latest updated UC Phase 2b results at 28 week is great, and many analysts increased PT.... It looks like time is near for J&J to announce buyout. Hope they do not sale for less than $100.
0 · Reply